Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Adaptive Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in Treatment-Naïve Adults Living With HIV-1

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Adaptive Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in Treatment-Naïve Adults Living With HIV-1

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VH 3739937 (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors ViiV Healthcare

    • Most Recent Events

    • 01 Oct 2024 Planned End Date changed from 26 Jun 2024 to 4 Nov 2024.
    • 01 Oct 2024 Planned primary completion date changed from 26 Jun 2024 to 4 Nov 2024.
    • 01 Oct 2024 Status changed from not yet recruiting to suspended. (Based on preliminary findings in a preclinical study of a similar maturation inhibitor, ViiV Healthcare have taken the decision to place the study 221773 of maturation inhibitor VH3739937 on temporary halt.)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top